High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniere's disease: a case series
High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniere's disease: a case series
复制标题
DOI：
10.1007/s00405-011-1647-2
复制
发表时间：
2011-08-01
影响因子：
2.6
通讯作者：
Strupp, Michael
中科院分区：
文献类型：
--
作者：
Lezius, Franziska;Adrion, Christine;Strupp, Michael
本研究的目的是评价高剂量盐酸倍他司汀（288-480 mg/天）治疗重度梅尼埃病（MD）患者的临床获益和副作用。在该病例系列中，11例对144 mg/天倍他司汀二盐酸盐剂量反应不充分的MD患者接受了288 - 480 mg倍他司汀二盐酸盐每日剂量的个体化治疗。每月的发作次数和副作用均受到监测。采用非参数检验进行统计分析。结果，所有患者的眩晕频率和严重程度均显著降低。副作用轻微，自限性，不需要改变治疗策略。尽管观察性研究有相当大的局限性，特别是在MD中，高剂量的盐酸倍他司汀在288和480 mg/天之间似乎对低剂量反应不充分的患者有效。此外，这样的剂量是良好耐受的。
The objective of this study was to evaluate the clinical benefit and the side effects of high dosages of betahistine dihydrochloride (288-480 mg/day) in patients with severe Meniere's disease (MD). In this case series 11 patients with MD who had not responded sufficiently to a dosage of 144 mg/day of betahistine dihydrochloride were treated on an individual basis with daily dosages between 288 and 480 mg of betahistine dihydrochloride. The number of attacks per month and the side effects were monitored. Non-parametric tests were used for statistical analysis. As a result, the frequency and the severity of vertigo were significantly reduced in all patients. The side effects were mild, self-limiting, and did not require any change in the treatment strategy. Despite the considerable limitations of an observational study-in particular in MD-high dosages of betahistine dihydrochloride between 288 and 480 mg/day seem to be effective in patients who do not sufficiently respond to lower dosages. Moreover, such dosages are well tolerated.